biote (NASDAQ:BTMD – Get Free Report) is projected to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect biote to post earnings of ($0.05) per share and revenue of $44.01 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.
biote (NASDAQ:BTMD – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.26). The firm had revenue of $44.23 million during the quarter, compared to analyst estimates of $46.12 million. biote had a negative return on equity of 22.33% and a net margin of 3.19%. On average, analysts expect biote to post $0.03 EPS for the current fiscal year and $0.17 EPS for the next fiscal year.
biote Stock Performance
BTMD stock opened at $1.11 on Monday. The company’s 50-day moving average price is $1.29 and its 200 day moving average price is $1.83. The company has a market cap of $39.88 million, a P/E ratio of 10.09 and a beta of 1.73. biote has a 52 week low of $1.00 and a 52 week high of $2.98.
Wall Street Analyst Weigh In
Several equities analysts have weighed in on BTMD shares. Weiss Ratings downgraded biote from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 13th. TD Cowen lowered their target price on shares of biote from $2.50 to $2.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Finally, B. Riley Financial decreased their price target on biote from $2.00 to $1.50 and set a “neutral” rating on the stock in a research note on Monday, August 10th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, biote presently has an average rating of “Moderate Buy” and an average target price of $2.50.
Check Out Our Latest Stock Analysis on BTMD
Insider Activity at biote
In other biote news, Chairman Marc Beer bought 115,950 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were acquired at an average price of $1.53 per share, with a total value of $177,403.50. Following the purchase, the chairman owned 223,744 shares in the company, valued at approximately $342,328.32. The trade was a 107.57% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 32.40% of the company’s stock.
About biote
Biote Inc (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services.
The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.
Featured Stories
- Five stocks we like better than biote
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.
